de Witte, T., Suciu, S., Meert, L., Halkes, C., Selleslag, D., Bron, D., . . . Baron, F. (2015). Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: A phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013). Ann Hematol.
Styl Chicagode Witte, Theo, et al. "Idarubicin and Cytarabine in Combination With Gemtuzumab Ozogamicin (IAGO) for Untreated Patients With High-risk MDS or AML Evolved From MDS: A Phase II Study From the EORTC and GIMEMA Leukemia Groups (protocol 06013)." Ann Hematol 2015.
Citace podle MLAde Witte, Theo, et al. "Idarubicin and Cytarabine in Combination With Gemtuzumab Ozogamicin (IAGO) for Untreated Patients With High-risk MDS or AML Evolved From MDS: A Phase II Study From the EORTC and GIMEMA Leukemia Groups (protocol 06013)." Ann Hematol 2015.